The latest developments in personalising healthcare. This is what’s happening in the world of MyCartis.
Performance of a Multiplex Serological Helicobacter pylori Assay on a Novel Microfluidic Assay Platform.
published by Proteomes, an Open Access Proteomics Journal from MDPI. Co-author: Joseph She, Science & Technology Director at MyCartis. Zwijnaarde, Belgium, October 10, 2017. “During assay development, the incubation times for the samples and the detection antibody were optimized in…> Read more
MyCartis appoints Philippe Stas as CEO Hilde Windels to join the Board of Directors as Executive Chair
The Belgium based immuno-diagnostic company MyCartis announced today it has strengthened its management team by appointing Philippe Stas as CEO and Hilde Windels as Executive Chair. Prior to joining MyCartis, Mr. Stas was CEO of Trinean, a life science…> Read more
The big revolution in healthcare today is that we are finally realizing that we are all equal, but not identical, certainly not at a molecular level.
MyCartis’ goal is to deliver innovative solutions for fast and cost effective identification of a patient’s specific signature of biomarkers. On our road to validate biomarkers on a larger scale, our intention is to build a bridge between research and medical practice by developing broadly available multiplexed biomarker solutions through technology (Evalution™) and bio-assays. The new multiplexing solution Evalution provides a ‘one technology fits all’ solution to enable researchers and assay developers to validate their biomarkers and to utilize and commercialize them. Evalution now provides anyone the opportunity to build multiplex assays for their biomarkers and to easily measure them in a fast, accurate and robust way.
The MyCartis technology jumps in exactly there where most biomarker programs end.> Read more
@MyCartis has moved to its new office! You can reach us via our new phone number +32 9 2779 888 and we are located… https://t.co/JPljTyq7Zb(about 9 days ago)
(about 9 days ago)
(about 20 days ago)
MyCartis technologies: accelerate innovation in biomarker analysis
MyCartis constantly develops technologies that push healthcare towards the next level of personalization. Not by ourselves, but by being part of a bigger network where we share ideas, knowledge and expertise. This allows us to accelerate innovation.> Evalution™
MyCartis applications: improve bioassays
MyCartis is committed to provide disruptive solutions in the fields of clinical and translational research for its customers and partners. By making biomarker assays simpler and faster, healthcare is already becoming more personalised.> Biomarkers
Evalution™ - the multiplexed analysis of biomarkers made fast and simple
Accelerate your research, trust your results
Evalution™ is MyCartis’ multiplex analysis platform tailored to the development of clinical biomarkers. It has been designed to analyze a broad range of protein and nucleic- acid based biomarkers to deliver high quality data and rapid results from minimal handling steps with unprecedented ease. Evalution™ integrates into a single instrument all the functions of incubation, washing, and optical readout for seamless operation of sophisticated assay protocols. The combination of customizable encoded microparticles with microfluidic assay plates in Evalution™ enables the analysis of proteins, nucleic-acids or other biomarkers.
The platform Evalution is intended for research use only – Not for diagnostic procedure> More Evalution™
MyCartis biomarker innovations
Protocols have been developed that enable a large variety of applications for the detection of proteins and nucleic acids such as sandwich immunoassays, (auto) antibody assays, genotyping, mutation analysis, m(i)RNA profiling. Novel proprietary biomarkers are in a late stage of protein biomarker pipeline and dedicated panels are in development for their validation. In parallel MyCartis is also developing research kits for a number of disease areas as part of it’s product pipeline.> Biomarker innovations